Affordable Access

Publisher Website

A panel of lung injury biomarkers enhances the definition of primary graft dysfunction (PGD) after lung transplantation.

  • Shah, Rupal J1
  • Bellamy, Scarlett L
  • Localio, A Russell
  • Wickersham, Nancy
  • Diamond, Joshua M
  • Weinacker, Ann
  • Lama, Vibha N
  • Bhorade, Sangeeta
  • Belperio, John A
  • Crespo, Maria
  • Demissie, Ejigayehu
  • Kawut, Steven M
  • Wille, Keith M
  • Lederer, David J
  • Lee, James C
  • Palmer, Scott M
  • Orens, Jonathan
  • Reynolds, John
  • Shah, Ashish
  • Wilkes, David S
  • And 2 more
  • 1 Pulmonary, Allergy, and Critical Care Division, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA. [email protected]
Published Article
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
Publication Date
Sep 01, 2012
DOI: 10.1016/j.healun.2012.05.001
PMID: 22694851


We aimed to identify combinations of biomarkers to enhance the definition of primary graft dysfunction (PGD) for translational research. Biomarkers reflecting lung epithelial injury (soluble receptor for advance glycation end products [sRAGE] and surfactant protein-D [SP-D]), coagulation cascade (plasminogen activator inhibitor-1 [PAI-1] and protein C), and cell adhesion (intracellular adhesion molecule-1 [ICAM-1]) were measured in the plasma of 315 individuals derived from the Lung Transplant Outcomes Group cohort at 6 and 24 hours after transplantation. We assessed biomarker utility in 2 ways: first, we tested the discrimination of grade 3 PGD within 72 hours; second, we tested the predictive utility of plasma biomarkers for 90-day mortality. PGD developed in 86 of 315 individuals (27%). Twenty-patients (8%) died within 90 days of transplantation, of which 16 (70%) had PGD. Biomarkers measured at 24 hours had greater discrimination than at 6 hours. Individually, sRAGE (area under the curve [AUC], 0.71) and PAI-1 (AUC, 0.73) had the best discrimination of PGD. The combinations of sRAGE with PAI-1 (AUC, 0.75), PAI-1 with ICAM-1 (AUC, 0.75), and PAI-1 with SP-D (AUC, 0.76) had the best discrimination. Combinations of greater than 2 biomarkers did not significantly enhance discrimination of PGD. ICAM-1 with PAI-1 (AUC, 0.72) and ICAM-1 with sRAGE (AUC, 0.72) had the best prediction for 90-day mortality. The addition of ICAM-1, PAI-1, or sRAGE to the concurrent clinical PGD grade significantly improved the prediction of 90-day mortality (p < 0.001 each). Measurement of the combination of a marker of impaired fibrinolysis with an epithelial injury or cell adhesion marker had the best discrimination for PGD and prediction for early death and may provide an alternative outcome useful in future research. Copyright © 2012 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Report this publication


Seen <100 times